Mapping the stage-specific plasma p53 interactome reveals colorectal cancer progression signatures and therapeutic vulnerabilities [0.03%]
绘制特定阶段的血浆p53互作蛋白图谱揭示结直肠癌进展标志物及治疗弱点
Raajesh Anand Natarajan,Siva Kaliyamoorthy,Vinoth Boopathi et al.
Raajesh Anand Natarajan et al.
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths worldwide, yet the molecular changes that occur in the bloodstream as the disease advances remain poorly understood. In particular, how p53-a key tumor suppressor-i...
ESR1 analysis of liquid biopsy in breast cancer, one-year routine experience of an Italian clinical referral center [0.03%]
意大利临床转诊中心乳腺癌液体活检中ESR1分析的一年常规经验
Thais Maloberti,Laura Poppi,Giulia Ciccimara et al.
Thais Maloberti et al.
Background: Activating mutations in the ESR1 gene are a known mechanism of secondary resistance to endocrine therapy in metastatic estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-)...
Crossing barriers with CSF-based sequencing for leptomeningeal disease in EGFR mutant NSCLC [0.03%]
基于脑脊液测序突破血脑屏障用于EGFR突变型非小细胞肺癌患者的脑膜转移检测
Bhuvan Chugh,Richa Dave,Aarthi Ramesh et al.
Bhuvan Chugh et al.
This case report highlights the critical role of cerebrospinal fluid (CSF)-based sequencing in precision oncology for a 64-year-old female with metastatic Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) wit...
Phenotype independent capture of circulating tumor cell using magnetic platelet decoys [0.03%]
利用磁性血小板诱饵捕获循环肿瘤细胞
Kenise Morris,Colette Li,Sasmit Sarangi et al.
Kenise Morris et al.
Circulating tumor cells (CTCs) are an essential biomarker for metastatic disease as they provide valuable information regarding the primary tumor, metastatic potential, potential prognosis, as well as aid in patient monitoring and guiding p...
Liquid biopsy biomarkers in cervical cancer: A systematic review and meta-analysis [0.03%]
宫颈癌液体活检标志物的系统评价和.meta.分析
Isaac Kinyua Njangiru,Bizhar Ahmed Tayeb,Hazhmat Ali et al.
Isaac Kinyua Njangiru et al.
Background/objectives: Liquid biopsy biomarkers are emerging as vital tools for cancer screening and diagnosis, offering a noninvasive and accurate approach to early malignancy detection. This study aimed to assess the di...
BLOODPAC's collaborations with European Union liquid biopsy initiatives [0.03%]
BLOODPAC与欧盟液体活检项目的合作
Jennifer Dickey,Elaine Katrivanos,Lauren C Leiman et al.
Jennifer Dickey et al.
The adoption of liquid biopsy into clinical practice has revolutionized the landscape of cancer diagnostics and treatment monitoring. In the U.S., the Blood Profiling Atlas in Cancer (BLOODPAC) has significantly supported the advancement of...
Cancer in a drop: Liquid biopsy highlights from the American Society of Clinical Oncology (ASCO) 2025 annual congress [0.03%]
一管见肿瘤：美国临床肿瘤学会（ASCO）2025年会上的液体活检研究亮点
Canio Martinelli,Roberto Borea,Maheswaran Shivahamy et al.
Canio Martinelli et al.
Over the past decade, liquid biopsy has progressively expanded its role in oncology, supported by mounting evidence demonstrating an increasing number of clinical applications. At the 2025 American Society of Clinical Oncology (ASCO) Annual...
Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling [0.03%]
一种用于临床全面基因组分析的灵敏度更高的液体活检检测方法的验证
Xavier S Bower,Jan Wignall,Matthew G Varga et al.
Xavier S Bower et al.
Recent advancements in precision oncology have affirmed the need for comprehensive genomic profiling (CGP) liquid biopsy assays with increased sensitivity, especially for detecting alterations in tumors which shed circulating tumor DNA (ctD...
Liquid biopsy- A pivotal test to help navigate clinical decisions at a precision center in India! [0.03%]
液体活检在印度精准医疗中心决策中的重要作用！
Sewanti Limaye,Aditya Shreenivas,Darshana Patil et al.
Sewanti Limaye et al.
Liquid biopsy, specifically circulating tumor DNA (ctDNA) analysis, has emerged as a transformative tool in precision oncology, providing real-time, minimally invasive characterizations of the tumor and tumor dynamics. While tissue biopsy i...
The diagnostic accuracy of next-generation sequencing in advanced NSCLC [0.03%]
下一代测序在晚期非小细胞肺癌中的诊断准确性
Elaine Yee-Ling Ko,Jason Wing Hon Wong,David Jen Hao Shih et al.
Elaine Yee-Ling Ko et al.
Background: Comprehensive genomic profiling is crucial for guiding treatment in advanced non-small cell lung cancer (NSCLC). However, tumor tissue-based targeted panel next-generation sequencing (TP-NGS) faces challenges,...